DK1296656T3 - Fremgangsmåde til fremstilling af et præparat - Google Patents

Fremgangsmåde til fremstilling af et præparat

Info

Publication number
DK1296656T3
DK1296656T3 DK01960323T DK01960323T DK1296656T3 DK 1296656 T3 DK1296656 T3 DK 1296656T3 DK 01960323 T DK01960323 T DK 01960323T DK 01960323 T DK01960323 T DK 01960323T DK 1296656 T3 DK1296656 T3 DK 1296656T3
Authority
DK
Denmark
Prior art keywords
preparation
composition
Prior art date
Application number
DK01960323T
Other languages
Danish (da)
English (en)
Inventor
Patrick Busson
Marco Schroeder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1296656(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1296656T3 publication Critical patent/DK1296656T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01960323T 2000-06-27 2001-06-18 Fremgangsmåde til fremstilling af et præparat DK1296656T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00113535 2000-06-27

Publications (1)

Publication Number Publication Date
DK1296656T3 true DK1296656T3 (da) 2006-11-27

Family

ID=8169074

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01960323T DK1296656T3 (da) 2000-06-27 2001-06-18 Fremgangsmåde til fremstilling af et præparat

Country Status (37)

Country Link
US (3) US6534087B2 (enExample)
EP (1) EP1296656B1 (enExample)
JP (2) JP4149803B2 (enExample)
KR (1) KR100557845B1 (enExample)
CN (1) CN1236764C (enExample)
AR (1) AR029278A1 (enExample)
AT (1) ATE334662T1 (enExample)
AU (2) AU2001281846B2 (enExample)
BR (1) BRPI0112014B1 (enExample)
CA (1) CA2411153C (enExample)
CY (1) CY1105714T1 (enExample)
CZ (1) CZ301813B6 (enExample)
DE (1) DE60121953T2 (enExample)
DK (1) DK1296656T3 (enExample)
EC (1) ECSP024401A (enExample)
EG (1) EG24141A (enExample)
ES (1) ES2269441T3 (enExample)
HR (1) HRP20021009B1 (enExample)
HU (1) HU229550B1 (enExample)
IL (2) IL153282A0 (enExample)
JO (1) JO2247B1 (enExample)
MA (1) MA26922A1 (enExample)
ME (1) MEP90608A (enExample)
MX (1) MXPA02012583A (enExample)
MY (1) MY129798A (enExample)
NO (1) NO332181B1 (enExample)
NZ (1) NZ523024A (enExample)
PE (1) PE20020101A1 (enExample)
PL (1) PL203804B1 (enExample)
PT (1) PT1296656E (enExample)
RU (1) RU2244542C2 (enExample)
SI (1) SI1296656T1 (enExample)
TW (1) TWI278325B (enExample)
UY (1) UY26799A1 (enExample)
WO (1) WO2002000201A2 (enExample)
YU (1) YU96602A (enExample)
ZA (1) ZA200209649B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
DE60121953T2 (de) * 2000-06-27 2007-03-08 F. Hoffmann-La Roche Ag Herstellungsverfahren von arzneizubereitungen
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
AU2003222814B2 (en) * 2002-04-26 2006-08-24 Cheplapharm Arzneimittel Gmbh Pharmaceutical composition comprising a lipase inhibitor and glucomannan
KR100517072B1 (ko) * 2002-11-25 2005-09-26 주식회사 태평양 폴리올/고분자 마이크로캡슐 및 이를 이용한 효소 안정화방법
US9174176B2 (en) 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
CA2548892C (en) * 2003-12-12 2015-10-27 Eran Eilat Compositions for treatment of ear disorders and methods of use thereof
EP1737405A2 (en) * 2004-04-06 2007-01-03 RPG Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
JP4329816B2 (ja) * 2004-09-15 2009-09-09 萬有製薬株式会社 サンプリング方法、サンプリング装置、ｌｏｇＤ測定方法及びｌｏｇＤ測定システム
US20100015057A1 (en) * 2004-12-31 2010-01-21 Mikhail Yurievich Gotovskiy Magnetoresonance preparations, device for individually selecting said preparations for increasing an organism life activity in actual environmental conditions
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US7984717B2 (en) * 2005-04-29 2011-07-26 Medtronic, Inc. Devices for augmentation of lumen walls
US20070060610A1 (en) * 2005-06-16 2007-03-15 Wempe Michael F Methods and pharmaceutical formulations for increasing bioavailability
WO2006136197A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Smoking device incorporating a breakable capsule, breakable capsule and process for manufacturing said capsule
WO2006136196A1 (en) * 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
EP1951186A4 (en) 2005-10-19 2009-11-04 Menni Menashe Zinger METHODS FOR TREATING HYPERHIDROSIS
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP1973406B1 (en) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
FR2895908B1 (fr) * 2006-01-12 2008-03-28 France Etat Procede de fabrication d'une forme pharmaceutique de phosphate d'oseltamivir
CN101389323B (zh) 2006-02-20 2013-08-21 中外制药株式会社 含有磷酸奥塞米韦的药物组合物
US7903256B2 (en) 2006-03-16 2011-03-08 Duke University Methods, systems, and computer program products for performing real-time quadrature projection based Fourier domain optical coherence tomography
CN1820744B (zh) 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100812824B1 (ko) 2006-09-27 2008-03-12 주식회사 제닉 키토산과 폴리에틸렌글리콜을 이용한 생체친화성 저독성필름
EP2117354B1 (en) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. A dry food product containing live probiotic
WO2008144565A1 (en) * 2007-05-18 2008-11-27 Tti Ellebeau, Inc. Transdermal delivery devices assuring an improved release of an active principle through a biological interface
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
CA2756883C (en) 2009-03-27 2018-01-09 Advanced Bionutrition Corp. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
RU2567668C2 (ru) 2009-05-26 2015-11-10 Эдванст Бионутришн Корпорейшн Стабильная сухая порошкообразная композиция, содержащая биологически активные микроорганизмы и/или биоактивные материалы, и способ ее изготовления
EP2482802A4 (en) * 2009-09-29 2013-08-07 Michael Burnet NEW PESTICIDE FORMULATIONS
KR100940745B1 (ko) * 2009-10-15 2010-02-04 광동제약 주식회사 오를리스타트 및 아타풀지트 함유 복합제의 코팅펠렛 및 이를 이용한 제제
EP2529004B1 (en) 2010-01-28 2017-06-07 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101021030B1 (ko) * 2010-03-25 2011-03-09 엘지이노텍 주식회사 형광체 코팅방법, 발광장치 제조방법 및 코팅된 형광체
US9404076B2 (en) * 2010-04-07 2016-08-02 Mitsubishi Gas Chemical Company, Inc. S-adenosyl-L-methionine-containing dry yeast composition with excellent storage stability and process for producing same
EP2603100B1 (en) 2010-08-13 2018-04-25 Advanced BioNutrition Corp. Dry storage stabilizing composition for biological materials
US9492387B2 (en) * 2010-10-29 2016-11-15 Western University Of Health Sciences Ternary mixture formulations
ES2610411T3 (es) 2011-03-01 2017-04-27 The Procter & Gamble Company Sustrato sólido poroso disgregable para aplicaciones para el cuidado de la salud personal
NZ628912A (en) 2012-03-23 2016-06-24 Advanced Bionutrition Corp Stabilizing composition for biological materials
CN103222964B (zh) * 2013-01-29 2014-10-08 青岛大学 一种奥利司他口服制剂及其制备方法
GB2524496A (en) * 2014-03-24 2015-09-30 British Airways Plc Dynamic tracking and control of passenger travel progress
JP6839666B2 (ja) 2015-06-25 2021-03-10 ネイティブ マイクロビアルズ， インコーポレイテッド 複雑な異種群集由来微生物株の解析、機能的な関係及びそれらの相互作用の予測及び同定、ならびにそれに基づく微生物アンサンブルの選択及び合成のための方法、装置、及びシステム
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
CA2994112C (en) 2015-07-29 2023-08-08 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物
CN110352250A (zh) 2016-12-28 2019-10-18 埃斯库斯生物科技股份公司 用于通过示踪剂分析法对复杂异质群落进行微生物株系分析、确定其功能关系及相互作用以及合成包括给药微生物群集和接种微生物群集的微生物群集的方法、设备和系统
CA3048246A1 (en) 2016-12-28 2018-07-05 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem SOLID GALENIC FORM, MOLDED, GASTRIC RETENTION AND EXTENDED RELEASE AND METHOD OF PREPARING THE SAME

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
US4489438A (en) * 1982-02-01 1984-12-18 National Data Corporation Audio response system
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
US5560921A (en) 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
NZ262562A (en) * 1993-02-23 1996-04-26 Warner Lambert Co Preparation of solvent free pharmaceutical compositions
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5536264A (en) * 1993-10-22 1996-07-16 The Procter & Gamble Company Absorbent composites comprising a porous macrostructure of absorbent gelling particles and a substrate
US5523106A (en) * 1994-02-03 1996-06-04 Nabisco, Inc. Juice-based expanded snacks and process for preparing them
CN102952033A (zh) 1995-02-27 2013-03-06 吉里德科学公司 新颖化合物,其合成方法及治疗用途
SG45864A1 (en) 1995-02-27 1999-04-27 Novel selective inhibitors of viral or bacterial neuraminidases
PL184823B1 (pl) * 1995-06-07 2002-12-31 Quadrant Holdings Cambridge Preparat do przechowywania substancji biologicznie aktywnych oraz sposób wytwarzania preparatu do przechowywania substancji biologicznie aktywnych
US5763483A (en) 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
ATE260646T1 (de) * 1996-04-16 2004-03-15 Novartis Consumer Health Sa Schnell zerfallende orale dosierungsform
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
EP0952820A1 (en) * 1996-10-14 1999-11-03 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JPH11137208A (ja) 1997-11-14 1999-05-25 Nikken Chem Co Ltd 口腔内速溶性固形物及びその製造方法
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CN1148169C (zh) * 1998-04-09 2004-05-05 弗·哈夫曼-拉罗切有限公司 通过溶于压缩气体和表面活性剂制备(亚)微米级粒子的方法
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
ES2217797T3 (es) * 1998-08-14 2004-11-01 F. Hoffmann-La Roche Ag Vinileteres heterociclicos contra trastornos neurologicos.
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
GB9904629D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
FR2791569B1 (fr) * 1999-03-31 2003-05-09 Pf Medicament Composition ou structure microporeuse expansee isotrope a dissolution rapide a usage pharmaceutique, veterinaire, dietetique, alimentaire ou cosmetique et son procede d'obtention
DE60121953T2 (de) * 2000-06-27 2007-03-08 F. Hoffmann-La Roche Ag Herstellungsverfahren von arzneizubereitungen

Also Published As

Publication number Publication date
HRP20021009B1 (hr) 2011-07-31
CY1105714T1 (el) 2010-12-22
MXPA02012583A (es) 2003-04-10
DE60121953D1 (de) 2006-09-14
ATE334662T1 (de) 2006-08-15
JP2004501184A (ja) 2004-01-15
HRP20021009A2 (en) 2004-02-29
UY26799A1 (es) 2001-12-28
DE60121953T2 (de) 2007-03-08
MY129798A (en) 2007-04-30
US20060134205A1 (en) 2006-06-22
US20020018812A1 (en) 2002-02-14
CN1438880A (zh) 2003-08-27
EG24141A (en) 2008-08-06
PL203804B1 (pl) 2009-11-30
AR029278A1 (es) 2003-06-18
NO20026197L (no) 2002-12-23
AU2001281846B2 (en) 2006-04-27
CN1236764C (zh) 2006-01-18
PE20020101A1 (es) 2002-02-12
ZA200209649B (en) 2004-03-10
US7074431B2 (en) 2006-07-11
KR20030023880A (ko) 2003-03-20
IL153282A (en) 2008-03-20
RU2244542C2 (ru) 2005-01-20
HK1058314A1 (en) 2004-05-14
PL365803A1 (en) 2005-01-10
BR0112014A (pt) 2003-05-13
HUP0302060A2 (hu) 2003-09-29
EP1296656A2 (en) 2003-04-02
WO2002000201A2 (en) 2002-01-03
ME00672B (me) 2011-12-20
NO332181B1 (no) 2012-07-16
JP4149803B2 (ja) 2008-09-17
PT1296656E (pt) 2006-12-29
CZ2003212A3 (cs) 2003-06-18
WO2002000201A3 (en) 2002-04-18
JO2247B1 (en) 2004-10-07
IL153282A0 (en) 2003-07-06
US20030039614A1 (en) 2003-02-27
AU8184601A (en) 2002-01-08
TWI278325B (en) 2007-04-11
MEP90608A (bs) 2011-12-20
EP1296656B1 (en) 2006-08-02
KR100557845B1 (ko) 2006-03-10
MA26922A1 (fr) 2004-12-20
ES2269441T3 (es) 2007-04-01
CA2411153C (en) 2007-01-30
SI1296656T1 (sl) 2006-12-31
HU229550B1 (en) 2014-01-28
YU96602A (sh) 2005-03-15
BRPI0112014B1 (pt) 2016-09-13
CA2411153A1 (en) 2002-01-03
NZ523024A (en) 2004-08-27
CZ301813B6 (cs) 2010-06-30
HUP0302060A3 (en) 2006-07-28
NO20026197D0 (no) 2002-12-23
JP2007302683A (ja) 2007-11-22
ECSP024401A (es) 2003-02-06
US6534087B2 (en) 2003-03-18

Similar Documents

Publication Publication Date Title
DK1296656T3 (da) Fremgangsmåde til fremstilling af et præparat
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1303478T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1326585T3 (da) Fremgangsmåde til fremstilling af pulverformuleringer
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1349580T3 (da) Fremgangsmåde til forbedring af stabiliteten af en farmaceutisk sammensætning
DK1277722T3 (da) Fremgangsmåde til fremstilling af methanol
DK1309581T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1253153T3 (da) Fremgangsmåde til fremstilling af 4"-substituerede-9-deoxo-9a-aza-9a-homoerythromycin-A-derivater
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1345939T3 (da) Fremgangsmåde til fremstilling af sulfonamidsubstituerede imidazotriazinoner
DK1272489T3 (da) Fremgangsmåde til præparation af cabergolins krystallinske form I
DK1263717T3 (da) Fremgangsmåde til fremstilling af methionin
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1446107T3 (da) Fremgangsmåde til fremstilling af tabletter omfattende s-adenosylmethionin
DK1296970T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1292586T3 (da) Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
DK1203000T3 (da) Fremgangsmåde til fremstilling af phosphonomethylglycin
DK1041081T3 (da) Fremgangsmåde til fremstilling af et præparat med höjt gangliosidindhold
DK1300160T3 (da) Fremgangsmåde til stabilisering af en sammensætning
DK1311494T3 (da) Kontinuerlig fremgangsmåde til fremstilling af chlorthiazolpesticider
DK1240173T3 (da) Fremgangsmåde til fremstilling af N-phosphonomethylglycin
DK1165483T3 (da) Fremgangsmåde til fremstilling af carbonylfluorid
DK1294694T3 (da) Fremgangsmåde til fremstilling af quinolinderivater
DK1254159T3 (da) Fremgangsmåde til fremstilling af acetylamidiniophenylalanylcyclohexylglycylpyridylalaninamider